Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2014 |
| Outros Autores: | , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/11065 |
Resumo: | National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA. |
| id |
CRUZ_a7d140e29e71e9afa6386a5597b65714 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/11065 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Olivier, Kenneth N.Shaw, Pamela A.Glaser, Tanya S.Bhattacharyya, DarshanaFleshner, MichelleBrewer, Carmen C.Zalewski, Christopher K.Folio, Les R.Siegelman, Jenifer R.Shallom, ShamiraPark, In KwonSampaio, Elisabeth P.Zelazny, Adrian M.Holland, Steven M.Prevots, D. Rebecca2015-07-03T12:34:37Z2015-07-03T12:34:37Z2014OLIVIER, Kenneth N. et al. Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. AnnalsATS, v.11, n.1, jan. 2014.https://www.arca.fiocruz.br/handle/icict/1106510.1513/AnnalsATS.201307-2310CengATS JournalsTratamentoAmikacinNontuberculous mycobacteriaTherapeuthicsAntibacterial agentsMicobactérias não TuberculosasAmicacinaInhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Diseaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleNational Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Biostatistics Research Branch. USA.Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Deafness and Other Communication Disorders. Otolaryngology Branch. Bethesda, MD, USA.National Institute of Deafness and Other Communication Disorders. Otolaryngology Branch. Bethesda, MD, USA.National Institutes of Health (NIH) . Department of Radiology and Imaging Sciences. Bethesda, MD, USA.Harvard Medical School. Brigham and Women’s Hospital. Department of Radiology. Boston, Massachussets, USA.National Institutes of Health. Clinical Center. Department of Laboratory Medicine. Microbiology Service. Bethesda, Maryland, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institutes of Health. Clinical Center. Department of Laboratory Medicine. Microbiology Service. Bethesda, Maryland, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA.Rationale: Treatment of pulmonary nontuberculous mycobacteria, especially Mycobacterium abscessus, requires prolonged, multidrug regimens with high toxicity and suboptimal efficacy. Options for refractory disease are limited. Objectives: We reviewed the efficacy and toxicity of inhaled amikacin in patients with treatment-refractory nontuberculous mycobacterial lung disease. Methods: Records were queried to identify patients who had inhaled amikacin added to failing regimens. Lower airway microbiology, symptoms, and computed tomography scan changes were assessed together with reported toxicity. Measurements and Main Results: The majority (80%) of the 20 patients who met entry criteria were women; all had bronchiectasis, two had cystic fibrosis and one had primary ciliary dyskinesia. At initiation of inhaled amikacin, 15 were culture positive for M. abscessus and 5 for Mycobacterium avium complex and had received a median (range) of 60 (6, 190) months of mycobacterial treatment. Patients were followed for a median of 19 (1, 50) months. Eight (40%) patients had at least one negative culture and 5 (25%) had persistently negative cultures. A decrease in smear quantity was noted in 9 of 20 (45%) and in mycobacterial culture growth for 10 of 19 (53%). Symptom scores improved in nine (45%), were unchanged in seven (35%), and worsened in four (20%). Improvement on computed tomography scans was noted in 6 (30%), unchanged in 3 (15%), and worsened in 11 (55%). Seven (35%) stopped amikacin due to: ototoxicity in two (10%), hemoptysis in two (10%), and nephrotoxicity, persistent dysphonia, and vertigo in one each. Conclusions: In some patients with treatment-refractory pulmonary nontuberculous mycobacterial disease, the addition of inhaled amikacin was associated with microbiologic and/or symptomatic improvement; however, toxicity was common. Prospective evaluation of inhaled amikacin for mycobacterial disease is warranted.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1914https://www.arca.fiocruz.br/bitstream/icict/11065/1/license.txt7d48279ffeed55da8dfe2f8e81f3b81fMD51ORIGINALelisabeth_sampaioetal_IOC_2014.pdfapplication/pdf526594https://www.arca.fiocruz.br/bitstream/icict/11065/2/elisabeth_sampaioetal_IOC_2014.pdf18ca5c7823941cadbe16275c4fdf4bceMD52TEXTelisabeth_sampaioetal_IOC_2014.pdf.txtelisabeth_sampaioetal_IOC_2014.pdf.txtExtracted texttext/plain30995https://www.arca.fiocruz.br/bitstream/icict/11065/3/elisabeth_sampaioetal_IOC_2014.pdf.txt514495bf8b05cccc24d0b7ceaf748096MD53icict/110652022-06-24 13:08:56.931oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-24T16:08:56Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease |
| title |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease |
| spellingShingle |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease Olivier, Kenneth N. Tratamento Amikacin Nontuberculous mycobacteria Therapeuthics Antibacterial agents Micobactérias não Tuberculosas Amicacina |
| title_short |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease |
| title_full |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease |
| title_fullStr |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease |
| title_full_unstemmed |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease |
| title_sort |
Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease |
| author |
Olivier, Kenneth N. |
| author_facet |
Olivier, Kenneth N. Shaw, Pamela A. Glaser, Tanya S. Bhattacharyya, Darshana Fleshner, Michelle Brewer, Carmen C. Zalewski, Christopher K. Folio, Les R. Siegelman, Jenifer R. Shallom, Shamira Park, In Kwon Sampaio, Elisabeth P. Zelazny, Adrian M. Holland, Steven M. Prevots, D. Rebecca |
| author_role |
author |
| author2 |
Shaw, Pamela A. Glaser, Tanya S. Bhattacharyya, Darshana Fleshner, Michelle Brewer, Carmen C. Zalewski, Christopher K. Folio, Les R. Siegelman, Jenifer R. Shallom, Shamira Park, In Kwon Sampaio, Elisabeth P. Zelazny, Adrian M. Holland, Steven M. Prevots, D. Rebecca |
| author2_role |
author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Olivier, Kenneth N. Shaw, Pamela A. Glaser, Tanya S. Bhattacharyya, Darshana Fleshner, Michelle Brewer, Carmen C. Zalewski, Christopher K. Folio, Les R. Siegelman, Jenifer R. Shallom, Shamira Park, In Kwon Sampaio, Elisabeth P. Zelazny, Adrian M. Holland, Steven M. Prevots, D. Rebecca |
| dc.subject.other.pt_BR.fl_str_mv |
Tratamento |
| topic |
Tratamento Amikacin Nontuberculous mycobacteria Therapeuthics Antibacterial agents Micobactérias não Tuberculosas Amicacina |
| dc.subject.en.pt_BR.fl_str_mv |
Amikacin Nontuberculous mycobacteria Therapeuthics Antibacterial agents |
| dc.subject.decs.pt_BR.fl_str_mv |
Micobactérias não Tuberculosas Amicacina |
| description |
National Institute of Allergy and Infectious Diseases. Laboratory of Clinical Infectious Diseases. Bethesda, MD, USA. |
| publishDate |
2014 |
| dc.date.issued.fl_str_mv |
2014 |
| dc.date.accessioned.fl_str_mv |
2015-07-03T12:34:37Z |
| dc.date.available.fl_str_mv |
2015-07-03T12:34:37Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
OLIVIER, Kenneth N. et al. Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. AnnalsATS, v.11, n.1, jan. 2014. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/11065 |
| dc.identifier.doi.pt_BR.fl_str_mv |
10.1513/AnnalsATS.201307-2310C |
| identifier_str_mv |
OLIVIER, Kenneth N. et al. Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. AnnalsATS, v.11, n.1, jan. 2014. 10.1513/AnnalsATS.201307-2310C |
| url |
https://www.arca.fiocruz.br/handle/icict/11065 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
ATS Journals |
| publisher.none.fl_str_mv |
ATS Journals |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/11065/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/11065/2/elisabeth_sampaioetal_IOC_2014.pdf https://www.arca.fiocruz.br/bitstream/icict/11065/3/elisabeth_sampaioetal_IOC_2014.pdf.txt |
| bitstream.checksum.fl_str_mv |
7d48279ffeed55da8dfe2f8e81f3b81f 18ca5c7823941cadbe16275c4fdf4bce 514495bf8b05cccc24d0b7ceaf748096 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009008857972736 |